Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Synergistic effects of ultrasound and Na<sup>+</sup> on soy protein isolate-hemp protein isolate-carboxymethyl cellulose composite emulsion gels: Evaluating the potential for low-salt gel foods.

International journal of biological macromolecules·2026
Same author

The MYC network: Hub of malignancy and blueprint for intervention.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Development and Validation of a Multivariable Nomogram Predictive of Kidney Function after Cardiopulmonary Resuscitation.

Kidney diseases (Basel, Switzerland)·2026
Same author

In Situ Fabricated Three-Dimensional Composite Electrode of Mo-Ni<sub>3</sub>S<sub>2</sub>/Nickel Foam for Enhanced Electrocatalytic Hydrogen Evolution.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Amorphous Ru-bda MCOF: A Frontier in Heterogeneous Molecular Catalysis for Water Oxidation.

Inorganic chemistry·2026
Same author

Targeting mitochondrial fission-autophagy axis in rheumatoid arthritis: leflunomide promote apoptosis of fibroblast-like synoviocytes.

Arthritis research & therapy·2026

相关实验视频

Updated: Mar 10, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K

虚拟查和MD模拟驱动的USP7抑制剂BML-284的发现

Tianyi Liu1, Wenxin Yan1,2, Xuejiao Hu1,2

  • 1Department of Pharmacy, Women and Children's Hospital of Dalian University of Technology, Dalian, Liaoning 116012, China.

ACS omega
|March 9, 2026
PubMed
概括

研究人员确定BML-284是一种强大的USP7抑制剂,用于治疗高危神经母细胞瘤 (NB). 这种药物向USP7-N-Myc轴,显示出显著的抗NB活性,并提供了一个新的治疗候选者.

更多相关视频

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

727
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K

相关实验视频

Last Updated: Mar 10, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K
Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

727
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 生物化学 生物化学

背景情况:

  • 高危神经母细胞瘤 (NB) 的预后不好,治疗选择有限.
  • 由于缺乏绑定口袋,直接针对N-Myc具有挑战性.
  • 一种稳定N-Myc的二基因酶USP7是一个可行的治疗标.

研究的目的:

  • 确定和验证新型USP7抑制剂用于高风险神经母细胞瘤治疗.
  • 研究已识别的抑制剂的作用机制.
  • 在临床前模型中评估BML-284的治疗潜力.

主要方法:

  • 一个7322个组合库的多阶段虚拟选 (HTVS/SP/XP对接+MM/GBSA).
  • 分子动力学 (MD),定向分子动力学 (SMD) 和雨采样 (美国) 模拟.
  • 在体外测试包括IC50测定,细胞增殖 (EdU),殖民地形成,迁移,亡标志物和DARTS实验.

主要成果:

  • BML-284对USP7.7具有很高的亲和力和稳定性.
  • BML-284有效地抑制了MYCN增强和非增强的NB细胞 (IC50:0.6278-1.410μmol/L).
  • BML-284通过降低USP7,N-Myc,MDM2,BCL-2的调节和上调Cleaved PARP-N/PARP来抑制NB细胞的增殖,殖民地形成和迁移,并诱导细胞亡.

结论:

  • BML-284是一种强大的USP7抑制剂,具有显著的抗神经母细胞瘤活性.
  • BML-284通过准USP7-N-Myc轴来发挥其作用.
  • BML-284代表了高风险神经母细胞瘤的有希望的治疗候选者.